Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | WRN | Q14191 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23385986 | 0.81 | MEN1 (0.46) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL10536534 | 0.81 | NAAA (0.40) | NAAAGAAMGAMSIMGAM2 | |
| SCHEMBL9166542 | 0.79 | MEN1 (0.44) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL16316315 | 0.77 | MEN1 (0.54) | MEN1KMT2ANAAAGAAMGAM | |
| SCHEMBL24851402 | 0.77 | MEN1 (0.43) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL18412192 | 0.77 | HCAR2 (0.43) | MEN1KMT2A | |
| SCHEMBL24850739 | 0.76 | MEN1 (0.41) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL18252661 | 0.76 | CYP2C9 (0.42) | MEN1KMT2AGAAMGAMSI | |
| SCHEMBL1965413 | 0.75 | — | — | |
| SCHEMBL21153532 | 0.74 | MEN1 (0.40) | MEN1KMT2AGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-26 | — | — | US | disclosed |
| US-9624160-B2 | Reactive ionic liquids | BASF SE (DE) | 2017-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025932-A1 | NOVEL FUNCTIONALIZED LACTONES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR3A | MEN1 3075/4885KMT2A 4370/4885NAAA 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.